Skip to main content

Advertisement

SpringerLink
Log in

Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

According to current World Health Organization (WHO) criteria, counting mitotic figures (MF), which is equal to the mitotic index (MI), on paraffin sections stained with hematoxylin and eosin (HE) is one of the recognized classification methods for meningiomas. However, it is not always easy to find the area of highest mitotic activity, and there are different perspectives among pathologists with regard to differentiating MF from non-MF, i.e., which are apoptotic figures and which are crushed or distorted cells. Moreover, there is an issue of overgrading in meningiomas with preoperative feeder embolization. Recently, anti-phosphohistone-H3 (PHH3) antibody has been reported as a mitosis-specific marker for meningioma grading. In this study, we attempted PHH3 immunostaining for our meningioma cases and verified not only the sensitivity of PHH3 immunostaining but also that of its usefulness in grading meningiomas. Forty-five initial histologically confirmed meningiomas (37 benign, 7 atypical, and 1 anaplastic) were reviewed according to current WHO criteria based on counting MF on HE-stained slides. PHH3-immunostained MF were counted in the same way, and the MIB-1 labeling index (LI) was calculated for each sample. PHH3-labeled MF were easily identified and permitted rapid recognition of the areas of highest mitotic activity. As a result, significant increase of PHH3 mitotic index (PHH3-MI) in comparison with HE mitotic index (HE-MI) and strong correlations with HE-MI to PHH3-MI as well as PHH3-MI to MIB-1 LI were demonstrated. Furthermore, no significant differences of PHH3-MI between cases with and without feeder embolization were demonstrated. As such, PHH3 may be a sensitive and useful marker for meningioma grading as based on the MF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kliehues P, Cavenee WK (2000) Pathology and genetics of tumors of the nervous system. International Agency for Research on Cancer (IARC), Lyon, pp 175–195

    Google Scholar 

  2. Perry A, Chicoine MR, Filiput E, et al (2001) Clinicopathologic assessment and grading of embolized meningiomas. A correlative study of 64 patients. Cancer (Phila) 92:701–711

    Article  CAS  Google Scholar 

  3. Ng HK, Poon WS, Goh K, et al (1996) Histopathology of postembolized meningiomas. Am J Surg Pathol 20:1224–1230

    Article  CAS  PubMed  Google Scholar 

  4. Hendzel MJ, Wei Y, Mancini MA (1997) Mitosis specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma (Berl) 106:348–360

    Article  CAS  Google Scholar 

  5. Shibata K, Inagaki M, Ajiro K (1990) Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structure. Eur J Biochem 192:87–93

    Article  CAS  PubMed  Google Scholar 

  6. Shibata K, Ajiro K (1993) Cell cycle-dependent suppressive effect of histone H1 on mitosis specific H3 phosphorylation. Eur J Biochem 268:18431–18434

    CAS  Google Scholar 

  7. Ribalta T, McCutcheon IE, Aldape KD, et al (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28:1532–1536

    Article  PubMed  Google Scholar 

  8. Kim YJ, Ketter R, Steudel WI, et al (2007) Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 128:118–125

    Article  CAS  PubMed  Google Scholar 

  9. Baehner R, Weidner N (2000) Enhanced mitotic figure counting in breast carcinomas using a mitosis-specific antibody: anti-phosphohistone-H3 (PHH3). Mod Pathol 13:17A

    Google Scholar 

  10. Colman H, Giannini C, Huang L, et al (2006) Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 30:657–664

    Article  PubMed  Google Scholar 

  11. Perry A, Scheithauer BW, Stafford SL, et al (1999) “Malignancy” in meningiomas. A clinicopathologic study of 116 patients, with grading implications. Cancer (Phila) 85:2046–2056

    CAS  Google Scholar 

  12. Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neurooncol 70:183–202

    Article  PubMed  Google Scholar 

  13. Goto H, Tomono Y, Ajiro K (1999) Identification of novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 274:25543–25549

    Article  CAS  PubMed  Google Scholar 

  14. Hirata A, Inada K, Tsukamoto T (2004) Characterization of a monoclonal antibody, HTA28, recognizing a histone H3 phosphorylation site as a useful marker of M-phase cells. J Histochem Cytochem 52:1503–1509

    Article  CAS  PubMed  Google Scholar 

  15. Gurley LR, D’Anna JA, Barhan SS, et al (1978) Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 84:1–15

    Article  CAS  PubMed  Google Scholar 

  16. Juan G, Traganos F, James WM, et al (1998) Histone H3 phosphorylation and expression of cyclones A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 32:71–77

    Article  CAS  PubMed  Google Scholar 

  17. Hendzel MJ, Nishioka WK, Raymond Y, et al (1998) Chromatin condensation is not associated with apoptosis. J Biol Chem 273:24470–24478

    Article  CAS  PubMed  Google Scholar 

  18. Kondziolka D, Bernstein M, Resch L, et al (1987) Significance of hemorrhage into brain tumors. Clinicopathological study. J Neurosurg 67:852–857

    Article  CAS  PubMed  Google Scholar 

  19. Perry A, Stafford SL, Scheithauer BW, et al (1998) The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer (Phila) 82:2262–2269

    Article  CAS  Google Scholar 

  20. Takahashi JA, Ueda T, Hashimoto N, et al (2000) The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 61:149–156

    Article  Google Scholar 

  21. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20: 22–39

    Article  CAS  PubMed  Google Scholar 

  22. Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461–469

    Article  CAS  PubMed  Google Scholar 

  23. Kuroiwa T, Tanaka H, Ohta T, et al (1996) Preoperative embolization of highly vascular brain tumors: clinical and histopathological findings. Noshuyo Byori 13:27–36

    CAS  PubMed  Google Scholar 

  24. Kai Y, Hamada J, Morioka M, et al (2002) Appropriate interval between embolization and surgery in patients with meningioma. Am J Neuroradiol 23:139–142

    PubMed  Google Scholar 

  25. Nasr MR, El-Zammar O (2008) Comparison of PHH3, Ki-67, and surviving immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 30:117–122

    Article  PubMed  Google Scholar 

  26. Tapia C, Kutzner H, Mentzel T, et al (2006) Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 30:83–89

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan

    Shintaro Fukushima, Mizuhiko Terasaki, Kiyohiko Sakata, Naohisa Miyagi & Minoru Shigemori

  2. Division of Pathology and Cell Biology, Graduate School and Faculty of Medicine, University of Ryukyus, Okinawa, Japan

    Seiya Kato

  3. Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan

    Yasuo Sugita

Authors
  1. Shintaro Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mizuhiko Terasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiyohiko Sakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naohisa Miyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seiya Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Sugita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Minoru Shigemori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shintaro Fukushima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukushima, S., Terasaki, M., Sakata, K. et al. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 26, 51–57 (2009). https://doi.org/10.1007/s10014-009-0249-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-009-0249-9

Key words

Search

Navigation